Biorestorative Therapies, Inc. (NASDAQ:BRTX) Sees Large Decline in Short Interest

Biorestorative Therapies, Inc. (NASDAQ:BRTX) was the target of a significant decline in short interest during the month of May. As of May 15th, there was short interest totaling 368,665 shares, a decline of 42.8% from the April 30th total of 644,870 shares. Based on an average daily volume of 1,050,694 shares, the days-to-cover ratio is presently 0.4 days. Approximately 1.7% of the company’s stock are short sold.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biorestorative Therapies in a research report on Wednesday, May 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Biorestorative Therapies Trading Down 12.8%

Shares of NASDAQ BRTX traded down $0.05 during midday trading on Tuesday, hitting $0.35. The company’s stock had a trading volume of 4,668,050 shares, compared to its average volume of 11,686,646. The stock has a fifty day moving average price of $0.26 and a 200 day moving average price of $0.66. Biorestorative Therapies has a one year low of $0.16 and a one year high of $2.05. The firm has a market capitalization of $9.03 million, a price-to-earnings ratio of -0.33 and a beta of 0.29.

Biorestorative Therapies (NASDAQ:BRTX) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.01. Biorestorative Therapies had a negative net margin of 3,088.27% and a negative return on equity of 508.42%. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.31 million. On average, equities research analysts predict that Biorestorative Therapies will post -0.66 earnings per share for the current fiscal year.

Institutional Trading of Biorestorative Therapies

Hedge funds and other institutional investors have recently modified their holdings of the business. Citadel Advisors LLC bought a new stake in shares of Biorestorative Therapies in the third quarter valued at approximately $152,000. DRW Securities LLC bought a new stake in shares of Biorestorative Therapies in the fourth quarter valued at approximately $55,000. Finally, Virtu Financial LLC raised its position in shares of Biorestorative Therapies by 102.4% in the third quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock valued at $35,000 after purchasing an additional 12,319 shares during the period. Institutional investors own 69.38% of the company’s stock.

Biorestorative Therapies Company Profile

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.